Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Dr Vose on the Safety of Epcoritamab in Relapsed/Refractory LBCL

March 12th 2025

Julie M. Vose, MD, MBA, highlights the safety of epcoritamab in patients with relapsed/refractory large B-cell lymphoma.

Anti-CD38-CAR-γδ T Cells Show Preclinical Cytotoxicity in Myeloma

March 12th 2025

Preclinical cytotoxicity was demonstrated with anti-CD38-CAR-gamma-delta T cells in multiple myeloma.

HCP Survey Outlines Challenges, Strategies for Venetoclax Initiation in CLL in the Community Setting

March 12th 2025

John M. Burke, MD, discusses identified challenges in the initiation of venetoclax in patients with CLL within a community-based setting.

SAR444200 Demonstrates Safety, Signals of Clinical Activity in Advanced GPC3+ HCC, Other Solid Tumors

March 11th 2025

SAR444200-mediated targeting of GPC3-expressing solid tumors was safe and showed early signs of antitumor activity in a phase 1/2 study.

Vepdegestrant Hits PFS End Point in ESR1-Mutated, ER+/HER2– Metastatic Breast Cancer

March 11th 2025

Vepdegestrant improved PFS in ESR1-mutated, ER-positive, HER2-negative metastatic breast cancer, but PFS was not improved in the ITT population.

Health Canada Approves Amivantamab/Lazertinib Combo for EGFR+ Advanced NSCLC

March 11th 2025

Amivantamab plus lazertinib was approved in Canada for first-line EGFR-mutated locally advanced or metastatic non–small cell lung cancer.

Dr Cortese on the Benefits of a Multiomic Evaluation of Immunologic Changes in CLL After Venetoclax

March 10th 2025

Matthew Cortese, MD, MPH, discusses the benefit of analyzing multiple biological layers when identifying immunologic changes in CLL after venetoclax.

Dr Richardson on the Role of Triplet Regimens in Newly Diagnosed Myeloma

March 10th 2025

Paul G. Richardson, MD, discusses the role of triplet regimens as the current standard of care in newly diagnosed multiple myeloma.

Same-Day Dosing of Eflapegrastim and Chemotherapy Is Safe, Reduces Duration of Severe Neutropenia in Early-Stage Breast Cancer

March 8th 2025

Same-day administration of eflapegrastim and cycle 1 of chemotherapy reduced the mean duration of severe neutropenia in early-stage breast cancer.

Frontline Palbociclib Combo Improves Outcomes in Real-World HR+/HER2-Negative Breast Cancer Population From Disadvantaged Areas

March 8th 2025

Palbociclib plus an AI prolonged OS and PFS in real-world patients with HR-positive/HER2-negative breast cancer from disadvantaged neighborhoods.

Sacituzumab Govitecan Upholds Efficacy and Safety in Real-World mTNBC Population

March 7th 2025

Treatment with sacituzumab govitecan was effective and tolerable in real-world patients with mTNBC who received the agent in later-line settings.

Dr Phull on the Rationale for the Retrospective Analysis of CAR T-Cell Therapy in R/R Myeloma

March 6th 2025

Pooja Phull, MD, discusses the rationale for assessing CAR T-cell therapy in the real-world vs trial setting in relapsed/refractory multiple myeloma.

Cell-Free DNA Blood-Based Assay Is Not Superior to Colonoscopy in Colorectal Cancer

March 6th 2025

Sewit Teckie, MD, discusses the advantages and disadvantages of a cfDNA blood-based assay compared with colonoscopy in diagnosing colorectal cancer.

Dr Shah on Disparities in Worldwide Bladder Cancer Trial Availability

March 5th 2025

Koral Shah, MD, details the rationale of evaluating worldwide disparities in bladder cancer clinical trial availability.

Nogapendekin Alfa Inbakicept/CAR-NK Wins FDA RMAT Designation for Lymphopenia Reversal in Metastatic Pancreatic Cancer

March 5th 2025

The FDA granted RMAT designation to nogapendekin alfa inbakicept/CAR-NK for lymphopenia reversal in patients with advanced or metastatic pancreatic cancer.

Norway Grants Marketing Authorization to Illuccix PSMA-PET Imaging Agent in Prostate Cancer

March 5th 2025

NOMA has approved the PET imaging agent for the identification of PSMA-positive lesions in patients with prostate cancer.

Dr Raghav on the Safety Profile of ABBV-400 Plus Chemo and Bevacizumab in Previously Treated mCRC

March 4th 2025

Kanwal P.S. Raghav, MBBS, MD, details the preliminary safety of a ABBV-400 regimen for the treatment of patients with previously treated mCRC.

Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS

March 4th 2025

Treatment with ivosidenib plus CPX-351 showed early efficacy in patients with relapsed/refractory AML or high-risk MDS harboring an IDH1 mutation.

Disparities in RCC Trial Access Illuminate the Need for Global Scientific Collaboration

March 3rd 2025

Regina Barragan-Carrillo, MD, discusses a study of RCC clinical trial availability and barriers to opening RCC clinical trials in lower-income countries.

Addition of CBM588 to Cabozantinib/Nivolumab Shows Potential in Metastatic RCC

March 3rd 2025

Hedyeh Ebrahimi, MD, MPH, highlights the early activity of CBM588 plus cabozantinib/nivolumab for the treatment of patients with metastatic RCC.